Evidence map›Paper›PMID 42339763›Full record

ArticleTherapeutic advances in respiratory disease

Impact of early therapeutic modality on 28-day mortality in immunocompromised patients with opportunistic pulmonary infections: a multicenter retrospective study.

Shiying Guo, Linlin Wang, Jinfang Shi, Xiaoyan Sai, Suping Tang, Jiajia Wang, Anqi Wang, Dong Qiu, Shuguang Han, Yan Wu and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shiying GuoDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Linlin WangDepartment of Respiratory and Critical Medicine, Taicang Hospital Affiliated to Soochow University, Suzhou, China.
Jinfang ShiDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaoyan SaiDepartment of Respiratory and Critical Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Suping TangDepartment of Respiratory and Critical Medicine, Central Hospital of Jiangnan University, Wuxi, China.
Jiajia WangDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-0554-1354
Anqi WangDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Dong QiuDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Shuguang HanDepartment of Respiratory and Critical Medicine, Central Hospital of Jiangnan University, No. 68, Zhongshan Road, Wuxi 214002, China.
Yan WuDepartment of Respiratory and Critical Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, No. 299, Qingyang Road, Wuxi 214023, China.
Cheng ChenDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou 215000, China.ORCID 0000-0002-9583-7991

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOpportunistic pulmonary infections remain a significant threat in immunocompromised cases.

objectivesThis study aims to evaluate the impact of early therapeutic modalities on 28-day mortality in non-AIDS and non-solid tumor immunocompromised patients hospitalized with opportunistic pulmonary infections, and to identify associated prognostic factors.

designThis multicenter retrospective study enrolled immunocompromised patients with opportunistic pulmonary infections from four respiratory centers between January 2022 and December 2024 to delineate their clinical characteristics and prognostic factors. The 28-day mortality was defined as the primary clinical outcome.

methodsMultivariate logistic analysis was utilized to identify the independent prognostic factors for 28-day mortality. Moreover, a predictive nomogram was constructed and validated.

resultsA total of 127 patients were included. Differences in pathogen distribution, laboratory tests at admission, and treatment strategies were identified between survivors and non-survivors. A multivariate analysis suggested that longer time from onset to pathogen-targeted therapy (OR: 1.047, 95% CI: 1.004-1.091,

conclusionEarly recognition, timely targeted antimicrobial therapy, and minimized glucocorticoid use are crucial to immunocompromised subjects suffering opportunistic pulmonary infections, which could prevent the escalation to ETI-IMV and septic shock, thereby reducing mortality.

Indexed as

Immunocompromised HostOpportunistic InfectionsRespiratory Tract InfectionsAgedFemaleGlucocorticoidsHumansMaleMiddle AgedNomogramsPrognosisRespiration, ArtificialRetrospective StudiesRisk FactorsTime FactorsGlucocorticoidsimmunocompromisednomogramopportunistic pulmonary infectionsoutcomesprognostic factors

Identifiers

PMID42339763
PMCPMC13305650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.